| 3.48 0.07 (2.05%) | 05-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.45 | 1-year : | 9.2 |
| Resists | First : | 5.52 | Second : | 7.88 |
| Pivot price | 3.75 |
|||
| Supports | First : | 1.71 | Second : | 1.42 |
| MAs | MA(5) : | 3.99  |
MA(20) : | 3.3 |
| MA(100) : | 3.18 |
MA(250) : | 8.23 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 31 |
D(3) : | 35.9 |
| RSI | RSI(14): 52.2 |
|||
| 52-week | High : | 17.84 | Low : | 1.71 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ENVB ] has closed above bottom band by 43.6%. Bollinger Bands are 107.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.13 - 4.16 | 4.16 - 4.18 |
| Low: | 3.35 - 3.38 | 3.38 - 3.4 |
| Close: | 3.45 - 3.49 | 3.49 - 3.52 |
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Tue, 05 May 2026
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model - Investing News Network
Tue, 05 May 2026
Enveric Highlights Preclinical PTSD Data Amid Rising Focus On Mental Health Therapies - Enveric Bioscienc - Benzinga
Sun, 03 May 2026
MSN Money - MSN
Sat, 02 May 2026
MSN Money - MSN
Sat, 02 May 2026
MSN Money - MSN
Fri, 01 May 2026
MSN Money - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 3.7 (%) |
| Held by Institutions | 5.9 (%) |
| Shares Short | 63 (K) |
| Shares Short P.Month | 94 (K) |
| EPS | -36.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.93 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -134.2 % |
| Return on Equity (ttm) | -304.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | 0.88 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|